Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma

Launched by XINXIN ZHANG · Apr 10, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new type of treatment for patients with a rare cancer called rhabdomyosarcoma, specifically for those whose disease has not responded to standard therapies. The trial will test a personalized mRNA vaccine, which is designed to help the body recognize and fight the cancer more effectively. It is suitable for patients aged 6 and older who have been diagnosed with rhabdomyosarcoma and have run out of other treatment options that can improve their survival or quality of life.

To be eligible for the trial, participants should have an expected survival of more than six months and a performance status that indicates they are generally well enough to participate. However, individuals with certain other active cancers or autoimmune diseases, as well as those with uncontrolled heart issues, will not be eligible. If someone joins the trial, they can expect to receive this personalized vaccine and be closely monitored for its effects on their condition. This study offers a potential new avenue of hope for patients facing this challenging diagnosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosed with rhabdomyosarcoma confirmed by pathological or molecular testing;
• • 2. Age ≥ 6 years;
• • 3. No known effective treatment available or no treatment proven to prolong survival with an acceptable quality of life;
• • 4. Expected survival time greater than 6 months;
• • 5. ECOG performance status score of 0-1; -
• Exclusion Criteria:
• • 1.History of or concurrent with other untreated malignant tumors, except for previously cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer; 2.History of or current active autoimmune diseases. 3.Has uncontrolled cardiovascular diseases.